Most Read Articles
Audrey Abella, 09 Jun 2017
Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Elvira Manzano, 14 Jun 2017
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Audrey Abella, 13 Jun 2017
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.

Maintenance CAP-B improves outcomes in mCRC across mutational subgroups

Jairia Dela Cruz
17 Jul 2017

Maintenance treatment with capecitabine plus bevacizumab (CAP-B) following six cycles of capecitabine, oxaliplatin and bevacizumab (CAPOX-B) in metastatic colorectal cancer (mCRC) patients appears to provide a survival benefit across all mutational subgroups, according to a posthoc analysis of the CAIRO3 study. The effect of CAP-B on survival is most pronounced in patients with RAS/BRAF wild-type and V600EBRAF-mutant tumours.

The phase III CAIRO3 study included a total of 557 previously untreated mCRC patients (median age 64 years; 65 percent male) with stable disease or better after six cycles CAPOX-B induction treatment. These patients were randomly assigned to either the group receiving CAP-B maintenance treatment (n=278) or the group subjected to only observation (n=279). Upon first progression, CAPOX-B was reintroduced until second disease progression. [Lancet 2015;385:1843-52]

In the present analysis, the authors defined patient subgroups according to RAS/BRAF mutation and mismatch repair (MMR) status, and subsequently examined its impact on CAP-B treatment efficacy. It was found that 240/420 (58 percent) of patients had RAS mutation, 36/381 (9 percent) had BRAF, and 4/279 (1 percent) had MMR deficiency. [Ann Oncol 2017;doi:10.1093/annonc/mdx322]

At a median follow-up of 87 months (interquartile range, 69 to 97), all mutational subgroups demonstrated a significant improvement in the primary endpoint of second progression-free survival (PFS2), defined as the interval between randomization and second disease progression while under CAPOX-B reintroduction.

Prognosis was found to be more favourable for patients with V600EBRAF-mutant (hazard ratio [HR], 0.28; 95 percent CI, 0.12 to 0.64; p=0.002) or RAS/BRAF wild-type tumours (HR, 0.57; 0.39 to 0.84; p=0.004) than for patients with RAS-mutant tumours (HR, 0.74; 0.55 to 0.98; p=0.038).

Maintenance CAP-B also produced significant improvements in the other endpoints investigated (interval between randomisation until first progression and interval between randomization until second progression on any treatment), with the exception of overall survival (OS).

“[T]he RAS/BRAF wild-type and V600EBRAF mutant subgroups showed significant [OS] benefit from maintenance treatment in contrast to the RAS mutant subgroup [HR, 0.68; p=0.047 and HR, 0.32; p=0.007 vs HR, 0.98; p=0.867],” the authors noted.

Finally, when mutational subgroup analyses were adjusted for sidedness rather than primary tumour location, both right-sided and left-sided tumours were found to derive significant benefit from maintenance CAP-B.

Despite being limited by a potential bias related to the unavailability of the RAS/BRAF mutation status and MMR status for all patients, the “findings suggest that all mutational subgroups derive a significant benefit from maintenance treatment, which was most pronounced in patients with RAS/BRAF wild-type or V600EBRAF-mutant tumours,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 09 Jun 2017
Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Elvira Manzano, 14 Jun 2017
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Audrey Abella, 13 Jun 2017
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.